<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104895</url>
  </required_header>
  <id_info>
    <org_study_id>APBI-IMRT-Florence</org_study_id>
    <nct_id>NCT02104895</nct_id>
  </id_info>
  <brief_title>Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation</brief_title>
  <official_title>Randomised Phase 3 Trial Of Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria Careggi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria Careggi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this Phase 3 randomised trial is to compare the efficacy and safety of whole
      breast radiotherapy to accelerated partial breast irradiation using intensity-modulated
      radiotherapy technique in selected early breast cancer patients after breast conserving
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The surgeons were requested to place clips at the borders of the surgical bed, using a
      minimum of four clips. The presence of surgical clips was a selection criterion to avoid
      geographic misses. Computed tomography (CT) scanning was performed using 0.3-cm thick-slices
      and a slice spacing of 0.3 cm.

      In patients assigned to APBI arm, the clinical target volume (CTV) was drawn with a uniform
      1-cm three-dimensional margin around the surgical clips. The CTV was limited to 3 mm from the
      skin surface and 3 mm from the lung-chest wall interface. A second uniform, three-dimensional
      1-cm margin was added to the CTV to obtain the planning target volume (PTV). The PTV was
      allowed to extend 4 mm inside the ipsilateral lung and was limited to 3 mm from the skin. The
      ipsilateral and contralateral breast, ipsilateral and contralateral lung, heart, and spinal
      cord were contoured as organs at risk.

      All the regions of interest were contoured according to the International Commission on
      Radiation Units and Measurements reports 50 and 62 recommendations. No respiratory control
      was used.

      Concerning the experimental Arm (accelerated partial breast irradiation), a dose of 30 Gy in
      five fractions at 6 Gy/fraction was prescribed.

      The following constraints were adopted for plan optimization: PTV coverage: 100% of PTV
      covered by 95% of the prescribed dose (V28.5 = 100%); maximal dose to PTV &lt;105% (31.5 Gy);
      minimal dose to PTV 28 Gy; uninvolved breast (i.e., ipsilateral breast without PTV): not &gt;50%
      covered by a dose of &gt;50% of the prescribed dose (V15 &lt;50%); ipsilateral lung: not &gt;20%
      covered by a dose &gt;10 Gy (V10&lt;20%); contralateral lung: not &gt;10% covered by a dose &gt;5 Gy
      (V5&lt;10%); contralateral breast: maximal dose &lt;1 Gy; heart: not &gt;10% covered by a dose &gt;3 Gy
      (V3 &lt;10%).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ipsilateral Breast Tumor Recurrence</measure>
    <time_frame>5-year</time_frame>
    <description>We defined local relapse (true recurrence) as the reappearance of the breast cancer in the index quadrant and ipsilateral breast tumours as any new breast cancer diagnosed in other quadrants of the same breast. The sum of local relapses and new ipsilateral breast tumours was defined as the ipsilateral breast tumour recurrence (IBTR). Locoregional tumour recurrence also included any recurrence in the ipsilateral axillary, supraclavicular, or internal mammary chain nodal regions.here we report the percentage of participants in each arm who experienced &quot;Ipsilateral Breast Tumor Recurrence&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Skin Toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Acute skin toxicity ≥ grade 2, here we report the percentage of participants in each arm who experienced &quot;Acute skin toxicity ≥ grade 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excellent Cosmesis</measure>
    <time_frame>5 years</time_frame>
    <description>Physician-rated cosmesis, Cosmetic outcome was scored on the four-category Harvard Breast Cosmesis Scale. An excellent cosmetic result score was assigned when the treated breast looked like the contralateral one; a good cosmetic score was assigned for minimal but identifiable radiation effects of the treated breast; a fair score was used if significant radiation effects were readily observable; a poor score was used for severe sequelae due to radiation effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">520</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Whole breast irradiation (WBI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional whole breast irradiation (WBI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Partial breast irradiation (APBI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Accelerated partial breast irradiation (APBI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Accelerated partial breast irradiation (APBI)</intervention_name>
    <description>Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)</description>
    <arm_group_label>Partial breast irradiation (APBI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole breast irradiation (WBI)</intervention_name>
    <description>Conventional whole breast irradiation (WBI)</description>
    <arm_group_label>Whole breast irradiation (WBI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at presentation &gt;40 y

          -  Tumor size &lt;25 mm

          -  Wide excision or quadrantectomy with clear margins (&gt;5 mm)

          -  Clips placed in tumor bed

          -  Full informed consent from patient

        Exclusion Criteria:

          -  Cardiac dysfunction

          -  Forced expiratory volume in 1 second (FEV1) &lt;1 L/m

          -  Extensive intraductal carcinoma

          -  Multifocal cancer

          -  Psychiatric problems

          -  Recurrent breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenzo Livi, Full Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florence University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Icro Meattini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria Careggi</affiliation>
  </overall_official>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <results_reference>
    <citation>Livi L, Buonamici FB, Simontacchi G, Scotti V, Fambrini M, Compagnucci A, Paiar F, Scoccianti S, Pallotta S, Detti B, Agresti B, Talamonti C, Mangoni M, Bianchi S, Cataliotti L, Marrazzo L, Bucciolini M, Biti G. Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized clinical trial. Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):509-15. doi: 10.1016/j.ijrobp.2009.04.070. Epub 2009 Aug 21.</citation>
    <PMID>19700248</PMID>
  </results_reference>
  <results_reference>
    <citation>Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, Paiar F, Scotti V, De Luca Cardillo C, Bastiani P, Orzalesi L, Casella D, Sanchez L, Nori J, Fambrini M, Bianchi S. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015 Mar;51(4):451-63. doi: 10.1016/j.ejca.2014.12.013. Epub 2015 Jan 17.</citation>
    <PMID>25605582</PMID>
  </results_reference>
  <results_reference>
    <citation>Meattini I, Saieva C, Marrazzo L, Di Brina L, Pallotta S, Mangoni M, Meacci F, Bendinelli B, Francolini G, Desideri I, De Luca Cardillo C, Scotti V, Furfaro IF, Rossi F, Greto D, Bonomo P, Casella D, Bernini M, Sanchez L, Orzalesi L, Simoncini R, Nori J, Bianchi S, Livi L. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Res Treat. 2015 Oct;153(3):539-47. doi: 10.1007/s10549-015-3565-2. Epub 2015 Sep 9.</citation>
    <PMID>26350524</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2014</study_first_posted>
  <results_first_submitted>November 25, 2015</results_first_submitted>
  <results_first_submitted_qc>May 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2016</results_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero-Universitaria Careggi</investigator_affiliation>
    <investigator_full_name>Lorenzo Livi</investigator_full_name>
    <investigator_title>Full Professor; Chief Radiotherapy-Oncology Unit; Florence University</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Early breast cancer</keyword>
  <keyword>Adjuvant breast cancer</keyword>
  <keyword>Accelerated partial breast irradiation</keyword>
  <keyword>Intensity modulated radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Whole Breast Irradiation (WBI)</title>
          <description>Conventional whole breast irradiation (WBI)
Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI)</description>
        </group>
        <group group_id="P2">
          <title>Partial Breast Irradiation (APBI)</title>
          <description>Accelerated partial breast irradiation (APBI)
Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="260"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Whole Breast Irradiation (WBI)</title>
          <description>Conventional whole breast irradiation (WBI)
Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI)</description>
        </group>
        <group group_id="B2">
          <title>Partial Breast Irradiation (APBI)</title>
          <description>Accelerated partial breast irradiation (APBI)
Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="260"/>
            <count group_id="B2" value="260"/>
            <count group_id="B3" value="520"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ipsilateral Breast Tumor Recurrence</title>
        <description>We defined local relapse (true recurrence) as the reappearance of the breast cancer in the index quadrant and ipsilateral breast tumours as any new breast cancer diagnosed in other quadrants of the same breast. The sum of local relapses and new ipsilateral breast tumours was defined as the ipsilateral breast tumour recurrence (IBTR). Locoregional tumour recurrence also included any recurrence in the ipsilateral axillary, supraclavicular, or internal mammary chain nodal regions.here we report the percentage of participants in each arm who experienced &quot;Ipsilateral Breast Tumor Recurrence&quot;</description>
        <time_frame>5-year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Whole Breast Irradiation (WBI)</title>
            <description>Conventional whole breast irradiation (WBI)
Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI)</description>
          </group>
          <group group_id="O2">
            <title>Partial Breast Irradiation (APBI)</title>
            <description>Accelerated partial breast irradiation (APBI)
Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Breast Tumor Recurrence</title>
          <description>We defined local relapse (true recurrence) as the reappearance of the breast cancer in the index quadrant and ipsilateral breast tumours as any new breast cancer diagnosed in other quadrants of the same breast. The sum of local relapses and new ipsilateral breast tumours was defined as the ipsilateral breast tumour recurrence (IBTR). Locoregional tumour recurrence also included any recurrence in the ipsilateral axillary, supraclavicular, or internal mammary chain nodal regions.here we report the percentage of participants in each arm who experienced &quot;Ipsilateral Breast Tumor Recurrence&quot;</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Skin Toxicity</title>
        <description>Acute skin toxicity ≥ grade 2, here we report the percentage of participants in each arm who experienced &quot;Acute skin toxicity ≥ grade 2</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Whole Breast Irradiation (WBI)</title>
            <description>Conventional whole breast irradiation (WBI)
Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI)</description>
          </group>
          <group group_id="O2">
            <title>Partial Breast Irradiation (APBI)</title>
            <description>Accelerated partial breast irradiation (APBI)
Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Skin Toxicity</title>
          <description>Acute skin toxicity ≥ grade 2, here we report the percentage of participants in each arm who experienced &quot;Acute skin toxicity ≥ grade 2</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Excellent Cosmesis</title>
        <description>Physician-rated cosmesis, Cosmetic outcome was scored on the four-category Harvard Breast Cosmesis Scale. An excellent cosmetic result score was assigned when the treated breast looked like the contralateral one; a good cosmetic score was assigned for minimal but identifiable radiation effects of the treated breast; a fair score was used if significant radiation effects were readily observable; a poor score was used for severe sequelae due to radiation effects</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Whole Breast Irradiation (WBI)</title>
            <description>Conventional whole breast irradiation (WBI)
Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI)</description>
          </group>
          <group group_id="O2">
            <title>Partial Breast Irradiation (APBI)</title>
            <description>Accelerated partial breast irradiation (APBI)
Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Excellent Cosmesis</title>
          <description>Physician-rated cosmesis, Cosmetic outcome was scored on the four-category Harvard Breast Cosmesis Scale. An excellent cosmetic result score was assigned when the treated breast looked like the contralateral one; a good cosmetic score was assigned for minimal but identifiable radiation effects of the treated breast; a fair score was used if significant radiation effects were readily observable; a poor score was used for severe sequelae due to radiation effects</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6"/>
                    <measurement group_id="O2" value="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5-years</time_frame>
      <desc>Acute and late skin toxicity, any grade</desc>
      <group_list>
        <group group_id="E1">
          <title>Whole Breast Irradiation (WBI)</title>
          <description>Conventional whole breast irradiation (WBI)
Whole breast irradiation (WBI): Conventional whole breast irradiation (WBI)</description>
        </group>
        <group group_id="E2">
          <title>Partial Breast Irradiation (APBI)</title>
          <description>Accelerated partial breast irradiation (APBI)
Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>acute skin toxicity, any grade</sub_title>
                <description>Here we report total rate of acute skin toxicity in each arm of the study</description>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>late skin toxicity, any grade</sub_title>
                <description>Here we report rate of late skin toxicity in each arm of the study</description>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="260"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Icro Meattini</name_or_title>
      <organization>Radiation-Oncology Unit, AOU Careggi, Florence University, Florence, Italy</organization>
      <phone>+39055794 ext 7719</phone>
      <email>icro.meattini@unifi.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

